Jørgensen will stay on as CEO temporarily for an undetermined period of time “to support a smooth transition” as the company looks for his replacement. Novo Nordisk’s value more than ...

In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company’s board as an observer ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." ...

As part of the transition period, Lars Rebien Sørensen ... with operating profit ranging from approximately $5.4 to $6.3 billion. 2 “Serving as Novo Nordisk’s CEO for the past eight years has been a ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...